BR9815302A - Método para diminuir a concentração de colesterol ldl e aumentar a concentração de colesterol hdl no sangue para reduzir o risco de aterosclerose e doença vascular - Google Patents

Método para diminuir a concentração de colesterol ldl e aumentar a concentração de colesterol hdl no sangue para reduzir o risco de aterosclerose e doença vascular

Info

Publication number
BR9815302A
BR9815302A BR9815302-1A BR9815302A BR9815302A BR 9815302 A BR9815302 A BR 9815302A BR 9815302 A BR9815302 A BR 9815302A BR 9815302 A BR9815302 A BR 9815302A
Authority
BR
Brazil
Prior art keywords
concentration
cholesterol
blood
risk
decrease
Prior art date
Application number
BR9815302-1A
Other languages
English (en)
Inventor
Susan M Potter
Edna C Henley
Doyle H Waggle
Original Assignee
Protein Tech Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Tech Int filed Critical Protein Tech Int
Publication of BR9815302A publication Critical patent/BR9815302A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/185Vegetable proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dairy Products (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Pyrane Compounds (AREA)

Abstract

"MéTODO PARA DIMINUIR A CONCENTRAçãO DE COLESTEROL LDL E AUMENTAR A CONCENTRAçãO DE COLESTEROL HDL NO SANGUE PARA REDUZIR O RISCO DE ATEROSCLEROSE E DOENçA VASCULAR" é proporcionado um método de alterar a concentração de constituintes de colesterol no sangue humano. Um material de daidzeína é administrado a um ser humano para aumentar a concentração de colesterol HDL, e para diminuir o nível de colesterol LDL no sangue. O material de daidzeína pode ser administrado em uma composição farmacêutica, ou em um suplemento dietético, incluindo os suplementos dietéticos à base de proteína da soja. A utilização de daidzeína para aumentar a concentração de colesterol HDL e diminuir a concentração de colesterol LDL no sangue reduz o risco de aterosclerose e doença vascular, proporcionando mais colesterol HDL benéfico para a saúde e reduzindo o nível de colesterol LDL que induz a aterosclerose.
BR9815302-1A 1997-09-19 1998-07-23 Método para diminuir a concentração de colesterol ldl e aumentar a concentração de colesterol hdl no sangue para reduzir o risco de aterosclerose e doença vascular BR9815302A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/933,788 US5855892A (en) 1997-09-19 1997-09-19 Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease

Publications (1)

Publication Number Publication Date
BR9815302A true BR9815302A (pt) 2000-10-17

Family

ID=25464506

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815302-1A BR9815302A (pt) 1997-09-19 1998-07-23 Método para diminuir a concentração de colesterol ldl e aumentar a concentração de colesterol hdl no sangue para reduzir o risco de aterosclerose e doença vascular

Country Status (9)

Country Link
US (1) US5855892A (pt)
EP (1) EP0903143A3 (pt)
JP (1) JPH11139973A (pt)
KR (1) KR19990029173A (pt)
CN (1) CN1102847C (pt)
AU (1) AU732095B2 (pt)
BR (1) BR9815302A (pt)
CA (1) CA2231292C (pt)
TW (1) TW486368B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0656786T3 (da) * 1992-05-19 2004-11-08 Novogen Res Pty Ltd Anvendelse af isoflavonphytoöstrogenekstrakter af soja eller klöver
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
WO1998050026A1 (en) * 1997-05-01 1998-11-12 Novogen Inc Treatment or prevention of menopausal symptoms and osteoporosis
US6320028B1 (en) 1997-10-15 2001-11-20 Central Soya Company, Inc. Soy isoflavone concentrate process and product
US6369200B2 (en) 1997-10-15 2002-04-09 Central Soya Company, Inc. Soy isoflavone concentrate process and product
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
DE69916414T2 (de) * 1998-07-16 2005-05-19 Aaron Tabor Sojazubereitungen und deren verwendung zur gesundheitsförderung
ATE242638T1 (de) 1998-11-25 2003-06-15 Nutri Pharma As Verwendung einer zusammensetzung enthaltend sojaprotein, diätfasern und phytoestrogen zur vorbeugung und/oder behandlung von lungenerkrankungen
WO2000030665A1 (en) * 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
US6413546B1 (en) 1999-03-18 2002-07-02 Indena, S.P.A. Tablets incorporating isoflavone plant extracts and methods of manufacturing them
EP1171119A1 (en) 1999-04-20 2002-01-16 The Board Of Trustees Of Southern Illinois University Methods of treating clinical diseases with isoflavones
US7285297B1 (en) 1999-04-23 2007-10-23 Archer-Daniels-Midland Company Method of reducing low density liproprotein cholesterol concentration
US6544566B1 (en) 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
JP4006133B2 (ja) * 1999-05-17 2007-11-14 松谷化学工業株式会社 可溶性イソフラボン組成物及びその製造方法
US20090233999A1 (en) * 1999-09-06 2009-09-17 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPQ266199A0 (en) * 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
AUPQ520300A0 (en) * 2000-01-21 2000-02-17 Novogen Research Pty Ltd Food product and process
WO2001091588A1 (fr) * 2000-05-30 2001-12-06 Societe Des Produits Nestle S.A. Composition primaire contenant un compose bioactif lipophile
US20050106219A1 (en) * 2000-05-30 2005-05-19 Karlheinz Bortlik Primary composition comprising a lipophilic bioactive compound
US20030082247A1 (en) * 2000-07-07 2003-05-01 Minoru Takebe Obesity inhibitory materials
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
EP1368024A4 (en) * 2001-03-16 2009-03-18 Novogen Res Pty Ltd TREATMENT OF RESTENOSIS
NZ529243A (en) * 2001-05-02 2007-11-30 Kgk Synergize Inc Use of polymethoxylated flavones for treating insulin resistance
JP2004533831A (ja) * 2001-06-13 2004-11-11 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー イソフラボノイド産生植物の植物の一部のイソフラボノイド特性を変化させる方法
US6787151B2 (en) 2001-08-10 2004-09-07 Lipton, Division Of Conopco, Inc. Composition for lowering blood cholesterol
US6586018B1 (en) * 2001-08-31 2003-07-01 Sabina Fasano Herbal composition
EP1491192A4 (en) * 2002-03-15 2007-08-15 Nichimo Kk COMPOSITIONS STRENGTHENING BIOLOGICAL ACTIVITY THAT CONTAIN AN ISOFLAVONE AGLYCONE FROM SOYBEAN GERMS
CN1662142A (zh) * 2002-04-18 2005-08-31 孟山都技术有限公司 用于减少心血管疾病风险的油体缔合蛋白质的组合物和方法及其用途
CN104643057A (zh) 2002-07-24 2015-05-27 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其用途
US8668914B2 (en) * 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US20040047927A1 (en) * 2002-09-05 2004-03-11 Yaguang Liu Soybean drug and new method of extracting soybean isoflavone
AU2003286781B2 (en) 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
AU2005239984B2 (en) * 2002-10-29 2010-06-03 Brigham Young University Use of equol for treating skin diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
WO2004045603A1 (ja) * 2002-11-21 2004-06-03 Nichimo Co., Ltd. 突発性難聴治療用の医薬組成物
KR100520408B1 (ko) * 2003-03-25 2005-10-10 주식회사 태평양 비만개선용 조성물
US20050013884A1 (en) * 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
US6998397B2 (en) * 2004-07-23 2006-02-14 Drebsk Comptech, Inc. Method for decreasing cholesterol level in blood
JP2006193459A (ja) * 2005-01-12 2006-07-27 Fancl Corp 血中コレステロール低下用経口組成物
US7695744B1 (en) 2005-11-16 2010-04-13 Kareem M Zubair Natural supplement of cholesterol lowering oil seeds and nuts and method of manufacture
WO2007065539A1 (en) * 2005-12-06 2007-06-14 Unilever Plc Extracts of gynostemma and compositions for reducing blood lipid levels
WO2007092735A2 (en) 2006-02-02 2007-08-16 Innovative Bio Therapies An extracorporeal cell-based therapeutic device and delivery system
US20090176871A1 (en) * 2008-01-07 2009-07-09 Schoenwetter Phillip E Treatments for Domestic Animals Having Sex Hormone Deficiencies Using Soy Germ Isoflavones
EP2291515A2 (en) * 2008-06-18 2011-03-09 Innovative Biotherapies, Inc. Methods for propagation of renal precursor cells
KR101307947B1 (ko) * 2011-11-30 2013-09-12 씨제이제일제당 (주) 싸이코스를 유효성분으로 하는 에쿠올 농도 상승제
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
CN104922271B (zh) * 2015-05-27 2018-05-04 广西壮族自治区中国科学院广西植物研究所 荔枝皮多酚在制备降低肝脏胆固醇的药物或保健品中的应用
CA3021695A1 (en) 2016-04-22 2017-10-26 Ripple Foods, Pbc Dairy product analogs and processes for making same
KR20200042284A (ko) * 2018-10-15 2020-04-23 (주)아모레퍼시픽 미네랄코티코이드 수용체 활성 저해용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548631A (en) * 1895-10-29 Sylvania
JPS4927872B1 (pt) * 1971-06-23 1974-07-22
JPS5985265A (ja) * 1982-11-04 1984-05-17 Naganoken Kooridoufu Kogyo Kyodo Kumiai 栄養強化食品素材の製造法
JPS59137421A (ja) * 1983-01-28 1984-08-07 Naganoken Kooridoufu Kogyo Kyodo Kumiai 生理活性物質の製造法
US4557927A (en) * 1983-03-10 1985-12-10 Kabushiki Kaisha Hoyashibara Food products and process for producing same
FR2543550B1 (fr) * 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
JPH0714927B2 (ja) * 1988-04-06 1995-02-22 キッコーマン株式会社 イソフラボン化合物の製造法
JPH05170756A (ja) * 1991-12-20 1993-07-09 Kikkoman Corp イソフラボン化合物の製造法
DK0656786T3 (da) * 1992-05-19 2004-11-08 Novogen Res Pty Ltd Anvendelse af isoflavonphytoöstrogenekstrakter af soja eller klöver
AU6635994A (en) * 1993-04-16 1994-11-08 Tufts University School Of Medicine Method for treatment of menopausal and premenstrual symptoms
RU2151775C1 (ru) * 1993-10-12 2000-06-27 Протеин Текнолоджиз Интернэшнл, Инк. Способ получения концентрата белка, способ извлечения изофлавона в концентрат белка, концентрат белка (варианты)
US5320949A (en) * 1993-10-12 1994-06-14 Protein Technologies International, Inc. Process for producing aglucone isoflavone enriched vegetable protein fiber
US6140469A (en) * 1993-10-12 2000-10-31 Protein Technologies International, Inc. Protein isolate having an increased level of isoflavone compounds and process for producing the same
EP0723536B2 (en) * 1993-10-12 2006-06-14 Archer Daniels Midland Company An aglucone isoflavone enriched vegetable protein whey, and process for producing
RU2142957C1 (ru) * 1993-10-12 1999-12-20 Протеин Текнолоджиз Интернэшнл, Инк. Способ получения экстракта, обогащенного изофлавоном аглюкона
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
AU3689095A (en) * 1994-10-03 1996-04-26 Schouten Industries B.V. Food and health products
US5516528A (en) * 1995-01-13 1996-05-14 Wake Forest University Dietary phytoestrogen in estrogen replacement therapy
IL115110A (en) * 1995-08-30 1997-08-14 Chajuss Daniel Soy molasses
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US5654011A (en) * 1996-07-30 1997-08-05 Energetics, Inc. Dietary supplements

Also Published As

Publication number Publication date
CN1102847C (zh) 2003-03-12
TW486368B (en) 2002-05-11
JPH11139973A (ja) 1999-05-25
CA2231292C (en) 2006-10-10
AU732095B2 (en) 2001-04-12
EP0903143A2 (en) 1999-03-24
EP0903143A3 (en) 1999-05-06
CN1212150A (zh) 1999-03-31
KR19990029173A (ko) 1999-04-26
AU6357498A (en) 1999-04-01
US5855892A (en) 1999-01-05
CA2231292A1 (en) 1999-03-19

Similar Documents

Publication Publication Date Title
BR9815302A (pt) Método para diminuir a concentração de colesterol ldl e aumentar a concentração de colesterol hdl no sangue para reduzir o risco de aterosclerose e doença vascular
BR0113367A (pt) Composição nutricional
Potter Overview of proposed mechanisms for the hypocholesterolemic effect of soy
Osman et al. Grape juice but not orange or grapefruit juice inhibits platelet activity in dogs and monkeys (Macaca fasciularis)
BR9707713A (pt) Composição e sua utilização como umm suplemento alimentar ou para reduzir o nìvel plasmático de lipìdios.
BR9915687A (pt) Composição compreendendo proteìna de soja,fibras de dieta e um composto fitoestrogênio eseu uso na prevenção e/ou tratamento de doençascardiovasculares
BR9810547A (pt) Absorção de minerais pelas células intestinais
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
PT721742E (pt) Nutricao para doentes idosos
BR9904796A (pt) Gordura contendo fitosterol
BR0309740A (pt) Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
Kowalski et al. Vitamin A hepatotoxicity: a cautionary note regarding 25,000 IU supplements
EP1748774B1 (en) Compositions comprising flavonoids and tocotrienols and uses thereof
Odeh et al. Natural antioxidants for the prevention of atherosclerosis
Blackburn Diet and atherosclerosis: Epidemiologic evidence and public health implications
DE69721497D1 (de) Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält
ATE220860T1 (de) Zusammensetzung zur unterdrückung von entzugssymptomen und alkoholabhängigkeit bei alkoholikern sowie prävention von alkoholmissbrauch bei gesunden personen
Nagai et al. Vitamin A toxicity secondary to excessive intake of yellow-green vegetables, liver and laver
BRPI0411436A (pt) composição, suplemento dietético, composição farmacêutica, e, métodos de tratamento para cáncer de fìgado, para danos ao fìgado causados por quimioembolização, e de um distúrbio do sistema hepatobiliar, e para cirrose e hepatite de fìgado
Leonhardt Effect of vitamin E on serum cholesterol and triglycerides in hyperlipidemic patients treated with diet and clofibrate
McCarron et al. Nonpharmacologic therapy in hypertension: from single components to overall dietary management
Leo et al. Re: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial
Holt Bone and Joint Health: Part 2—Dietary Supplements
RU98105515A (ru) Способ уменьшения концентрации ldl-холестерина и увеличения концентрации hdl-холестерина в крови для уменьшения риска атеросклероза и сосудистых заболеваний
Wretlind et al. Nutrition & Metabolism

Legal Events

Date Code Title Description
TE Change of address
B25D Requested change of name of applicant approved

Owner name: SOLAE, LLC (US)

Free format text: ALTERADO DE: PROTEIN TECHNOLOGIES INTERNATIONAL, INC.

B25A Requested transfer of rights approved

Owner name: ARCHER-DANIELS-MIDLAND COMPANY (US)

Free format text: TRANSFERIDO DE: SOLAE, LLC

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/35 (2006.01), A61P 3/06 (2006.0